Darolutamide is an androgen receptor signaling inhibitor with a different structure than other androgen receptor antagonists. It has been demonstrated that darolutamide inhibits translocation of androgen receptors to the nucleus which is induced by testosterone.Darolutamide treatment with ADT and, docetaxel chemotherapy is effective and has a tolerable safety profile in individuals with mHSPCa. When combined with docetaxel and ADT, darolutamide improves overall survival while having comparable adverse effect rates.